Atea Pharmaceuticals Inc. (AVIR) NASDAQ
$3.70 (0.01) (-0.27%)
Market Cap: $312.47M
As of 05/16/24 03:59 PM EDT. Market closed.
Atea Pharmaceuticals Inc. (AVIR)
NASDAQ
$3.70
(0.01) (-0.27%)
Market Cap: $312.47M
As of 05/16/24 03:59 PM EDT. Market closed.
Add to Portfolio
atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
60
Address
.
PRICE CHART FOR ATEA PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.72
Previous Close
$3.71
Days Range
$3.65 - $3.92
52 week range
$2.77 - $5.19
Volume
523,825
Avg. Volume (30 days)
239,447
Market Cap
$312.47M
Dividend Yield
-
P/E
-
Shares Outstanding
84,223,100
Open
$3.72
Previous Close
$3.71
Days Range
$3.65 - $3.92
52 week range
$2.77 - $5.19
Volume
523,825
Avg. Volume (30 days)
239,447
Market Cap
$312.47M
Dividend Yield
-
P/E
-
Shares Outstanding
84,223,100
FINANCIAL STATEMENTS FOR ATEA PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ATEA PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Corcoran Andrea | See Remarks | Feb 01, 2024 | Sale | $3.84 | 15,843 | 60,915 | 670,208 | Feb 02, 2024, 09:31 PM |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Feb 01, 2024 | Sale | $3.85 | 56,910 | 218,819 | 116,557 | Feb 02, 2024, 09:30 PM |
| Horga Maria Arantxa | Chief Medical Officer | Feb 01, 2024 | Sale | $3.84 | 15,870 | 60,963 | 25,664 | Feb 02, 2024, 09:29 PM |
| Foster Wayne | EVP, Chief Accounting Officer | Feb 01, 2024 | Sale | $3.84 | 12,477 | 47,904 | 20,857 | Feb 02, 2024, 09:26 PM |
| Vavricka John | Chief Commercial Officer | Feb 01, 2024 | Sale | $3.84 | 11,819 | 45,420 | 21,515 | Feb 02, 2024, 09:25 PM |
| Hammond Janet MJ | Chief Development Officer | Feb 01, 2024 | Sale | $3.84 | 14,029 | 53,913 | 35,362 | Feb 02, 2024, 09:24 PM |
| BERGER FRANKLIN M | Director | Nov 14, 2022 | Sale | $5.16 | 16,166 | 83,352 | 778,353 | Nov 15, 2022, 08:00 PM |
| BERGER FRANKLIN M | Director | Nov 11, 2022 | Sale | $5.15 | 25,500 | 131,333 | 794,519 | Nov 15, 2022, 08:00 PM |
| Murphy Polly A. | Director | Dec 20, 2021 | Buy | $8.57 | 12,000 | 102,796 | 23,295 | Dec 21, 2021, 09:41 PM |
| Rock Springs Capital Management LP | 10% Owner | Nov 03, 2020 | Buy | $24.00 | 250,000 | 6,000,000 | 1,654,724 | Nov 04, 2020, 04:05 PM |
| Hack Andrew A. F. | Director | Nov 03, 2020 | Buy | $24.00 | 250,000 | 6,000,000 | 5,615,659 | Nov 03, 2020, 09:36 PM |
| BERGER FRANKLIN M | Director | Nov 03, 2020 | Buy | $24.00 | 41,666 | 999,984 | 820,019 | Nov 03, 2020, 08:09 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Corcoran Andrea | See Remarks | 02/01/2024 | 60,915 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | 02/01/2024 | 218,819 |
| Horga Maria Arantxa | Chief Medical Officer | 02/01/2024 | 60,963 |
| Foster Wayne | EVP, Chief Accounting Officer | 02/01/2024 | 47,904 |
| Vavricka John | Chief Commercial Officer | 02/01/2024 | 45,420 |
| Hammond Janet MJ | Chief Development Officer | 02/01/2024 | 53,913 |
| BERGER FRANKLIN M | Director | 11/14/2022 | 83,352 |
| BERGER FRANKLIN M | Director | 11/11/2022 | 131,333 |
| Murphy Polly A. | Director | 12/20/2021 | 102,796 |
| Rock Springs Capital Management LP | 10% Owner | 11/03/2020 | 6,000,000 |
| Hack Andrew A. F. | Director | 11/03/2020 | 6,000,000 |
| BERGER FRANKLIN M | Director | 11/03/2020 | 999,984 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ATEA PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 9,243,306 | 0.00087% | -2.12% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,882,480 | 0.0007% | 4.12% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 1,123,400 | 0.00713% | -24.92% | Other |
| D. E. SHAW & CO., INC. | 207,759 | 0.00072% | 12.19% | Other |
| ALPS ADVISORS INC | 59,367 | 0.0017% | 1.59% | Other |
CHANGE IN SHARES OUTSTANDING FOR ATEA PHARMACEUTICALS INC
STOCK BUYBACKS FOR ATEA PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.04%
1Q
06/30/2023
0.04%
2Q
03/31/2023
0.12%
3Q
12/31/2022
0.18%
4Q
09/30/2022
0.21%
5Q
06/30/2022
0.21%
6Q
03/31/2022
0.31%
7Q
12/31/2021
-4.77%
8Q
09/30/2021
0.75%
9Q
06/30/2021
-5.28%
10Q
03/31/2021
-6.36%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ATEA PHARMACEUTICALS INC
LOADING...